GATA1 and acute myeloid leukemia: Finally, to evaluate possible clinical implications to our findings, SDHC variants levels were measured at diagnosis (acute stage of the disease) and at remission in bone marrow specimens of an AML patient whom, in a previous study, we had analyzed for GATA-1 and SDHC expression levels [6].